Mental health awareness takes center stage in Versailles
VERSAILLES, Ky. (FOX 56) — They say music heals the soul.
In Versailles on Saturday, that's just what was happening at 'Healing Notes,' a benefit concert for suicide prevention from the Kentucky Chapter of the American Foundation for Suicide Prevention.
'Music is a very healing component,' said Event Coordinator Allie Buchanan. 'That's why we named the event Healing Notes. And I think that feeling, that connection, a lot of times when we don't have the words to say, we have the music to sing. And I think that this type of event really brings that into focus.'
People from all over the community came out to enjoy food, drinks, and, of course, live music. All for a cause that some of them may not have a direct connection to, but many others do.
Mental health awareness takes center stage in Versailles
1 drowns after falling into Kentucky river
Woman accused hitting Ky. police cruiser 'intentionally' in multi-county DUI chase
Buchanan said she lost her grandfather to suicide in 2014.
'My wife, Susan Rogers, and myself we lost our daughter, Chloe, to suicide in June of '20,' said Kent Rogers, founder of Chloe's Petals for Hope.
The organization was created by the Rogers family to keep their daughter Chloe's memory alive and raise awareness for mental health and suicide prevention.
As a parent, losing a child to suicide is an unimaginable loss, but Rogers shared words of hope with FOX 56.
'You do matter. There are people that love you, that care about you, and you know, if you're not here, there would be people that would miss you deeply. And just, you know, to always just hold on and to know that, you know, It might be a bad day. It's not a bad life,' he said.
Organizers said Healing Notes is a prelude to their Out of the Darkness walk in October, and they will take advantage of any opportunity to shine a light on mental health, emphasizing it's a major health issue that you can't always see just by looking at a person suffering from it.
Read more of the latest Kentucky news
Buchanan said, 'A lot of people who suffer with mental health issues and depression, like myself and many of my family members, they can get in that rut of feeling like they're constantly in the dark and not having anyone to talk to you or any light at the end of their tunnel. And this is just a way to say, 'We see you, we hear you, and we would love to hear your story.''
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Most Chronic Hepatitis B Diagnoses in US Are Late
More than 75% of chronic hepatitis B diagnoses in the United States occur late — within 2 years before or after the onset of a liver complication — highlighting the need for improved screening to prevent poor outcomes. METHODOLOGY: Late diagnosis of chronic hepatitis B represents a missed opportunity to intervene early and prevent liver-related complications. Researchers conducted a retrospective analysis of the Truven MarketScan database (2007 to 2021) to estimate the prevalence of late diagnosis of chronic hepatitis B in the US and associated liver complications. Eligible patients had chronic hepatitis B diagnosis and at least 12 months of insurance coverage prior to the first liver complication (cirrhosis, hepatocellular carcinoma [HCC], or liver transplant). A diagnosis was defined as late if it occurred within 2 years before or after the first liver complication, and non-late if was made more than 2 years before the complication. TAKEAWAY: Of 2608 patients included (mean age, 54.83 years; 29.7% women), 76.6% had a late diagnosis of chronic hepatitis B; among these, 44.5% were diagnosed at or within 6 months of their first liver complication, and 75.5% lacked a documented visit to a medical provider prior to their first liver complication. Among those diagnosed > 36 months after the first liver complication, 46% already had another liver disease. Despite treatment advances, the rate of late diagnosis remained stable between 2010 (78.8%) and 2019 (89.3%; P for trend = . 438). for trend 438). Among patients with a late diagnosis, 91.0% had cirrhosis, 81.5% had decompensated cirrhosis, 30.8% developed HCC, and 14.4% underwent liver transplant. Independent predictors of late diagnosis included male sex, alcohol use, and having Preferred Provider Organization (PPO) or Health Maintenance Organization/PPO hybrid insurance. IN PRACTICE: 'Our study suggests that the majority of [hepatitis B virus] diagnoses in the United States are likely incidental from the work-up of a liver complication. These patients can be seen as 'missed opportunities' for treatment and intervention to prevent disease progression and adverse hepatic outcomes,' the authors wrote. SOURCE: This study was led by Michael Le and Joanne K. Liu, Stanford University Medical Center, Stanford, California. It was published online in Alimentary Pharmacology & Therapeutics . LIMITATIONS: This study excluded uninsured individuals and those covered by government insurance (eg, Medicaid), potentially underrepresenting higher-risk populations. Reliance on claims data may have affected the accuracy of diagnosis rates. Data on race, ethnicity, and foreign-born status were unavailable, preventing analysis of these important factors. DISCLOSURES: The authors received no specific funding for this work. No conflicts of interest were disclosed by the authors.
Medscape
2 hours ago
- Medscape
Adverse Events Post-Colonoscopy Rise With Age but Are Rare
Although adverse event rates within 30 days after surveillance colonoscopy increase with age, peaking among patients aged 76-85 years, they remain infrequent, occurring in < 1% of procedures. METHODOLOGY: Guidelines recommend surveillance colonoscopy for patients with precancerous adenomas due to an increased colorectal cancer risk but lack recommendations for stopping surveillance after the age of 75 years despite older adults experiencing increased comorbidities. Researchers analyzed data from 84,172 surveillance colonoscopies performed from 2010 to 2019 within a large integrated US healthcare system. Participants (59.5% men; 66.4% White individuals), aged 45-85 years, had a prior adenoma and were followed up to 30 days post-procedure for adverse events. Outcomes included emergency department visits, hospitalizations, and deaths due to specific conditions (eg, colonic perforation and stroke), cardiovascular conditions, or any cause. Logistic regression was used to assess the association between age and adverse event risk, adjusting for various factors. TAKEAWAY: Adverse events occurred in < 1% of procedures, with gastrointestinal bleeding being the most common. Adverse event rates increased with age, with the highest rates observed in patients aged 76-85 years (69.6 events per 10,000 procedures), particularly for gastrointestinal bleeding (39.2 events per 10,000 procedures) and stroke (18.3 events per 10,000 procedures). Patients aged 76-85 years had significantly higher odds of adverse events than younger age groups in unadjusted analyses, but these odds were attenuated after adjusting for covariates. Significant risk factors for adverse events across all age groups included anticoagulant use, higher comorbidity scores, polypectomy, and advanced neoplasia detection during surveillance colonoscopy. IN PRACTICE: 'The findings suggest that the decision to perform colonoscopy surveillance after age 75 should be individualized based on patient preference, prior colonoscopy findings and procedure quality, comorbidities, and medication usage, rather than age alone,' the authors wrote. SOURCE: This study was led by Jeffrey K. Lee, MD, Kaiser Permanente Northern California in Oakland, California. It was published online in Clinical Gastroenterology and Hepatology . LIMITATIONS: Findings may not be generalizable, as all participants were insured and had access to comprehensive care. The observational design lacked a noncolonoscopy comparison group, making it difficult to attribute adverse events directly to the procedure. Limited numbers of certain adverse events resulted in wide CIs, and potential confounders like polyp size or number and sedation type were not adjusted for. DISCLOSURES: This study was conducted within the National Cancer Institute-funded Population-based Research to Optimize the Screening Process consortium and supported by a career development grant from the same agency. The authors reported no relevant conflicts of interest.
Medscape
3 hours ago
- Medscape
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology (ASCO) 2025 annual meeting. The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA (ctDNA). METHODOLOGY: The phase 3 CheckMate 816 trial has shown that compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint. The median follow-up duration was 68.4 months. TAKEAWAY: The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% (hazard ratio [HR], 0.72; P = .048). = .048). Among patients who received the combination therapy, the 5-year overall survival rate was 95.3% for those who achieved a pathological complete response vs 55.7% for those who did not. Overall, 24% of patients in the nivolumab group achieved a pathological complete response vs only 2.2% in the chemotherapy group. ctDNA clearance before surgery was a strong prognostic indicator, regardless of treatment. At 5 years, overall survival was 75.0% among patients with ctDNA clearance vs 52.6% in those without (HR for death, 0.38 in the nivolumab group and 0.39 in the chemotherapy-only group). The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths related to a trial treatment. IN PRACTICE: 'In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,' the authors wrote. 'These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient's life when paired with the curative potential of surgical resection.' SOURCE: This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland, was published online in The New England Journal of Medicine and presented at ASCO. LIMITATIONS: Although the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings. DISCLOSURES: This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb.
